Literature DB >> 11905811

How can immunology contribute to the control of tuberculosis?

S H Kaufmann1.   

Abstract

Tuberculosis poses a significant threat to mankind. Multidrug-resistant strains are on the rise, and Mycobacterium tuberculosis infection is often associated with human immunodeficiency virus infection. Satisfactory control of tuberculosis can only be achieved using a highly efficacious vaccine. Tuberculosis is particularly challenging for the immune system. The intracellular location of the pathogen shields it from antibodies, and a variety of T-cell subpopulations must be activated to challenge the bacterium's resistance to antibacterial defence mechanisms. A clear understanding of the immune responses that control the pathogen will be important for achieving optimal immunity, and information provided by functional genome analysis of M. tuberculosis will be vital in the design of a future vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11905811     DOI: 10.1038/35095558

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  209 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  BTLA exhibits immune memory for αβ T cells in patients with active pulmonary tuberculosis.

Authors:  Jin-Cheng Zeng; Dong-Zi Lin; Lai-Long Yi; Gan-Bin Liu; Hui Zhang; Wan-Dang Wang; Jun-Ai Zhang; Xian-Jing Wu; Wen-Yu Xiang; Bin Kong; Zheng W Chen; Cong-Yi Wang; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

3.  Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells.

Authors:  Gucheng Zeng; Crystal Y Chen; Dan Huang; Shuyu Yao; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

4.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

5.  Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines.

Authors:  Sushila D'Souza; Marta Romano; Johanna Korf; Xiao-Ming Wang; Pierre-Yves Adnet; Kris Huygen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

6.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 7.  [Immunology of tuberculosis: impact on the development of novel vaccines].

Authors:  T Ulrichs; S H E Kaufmann
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 8.  [Pathomorphogenesis of tubercular histologic changes: mechanisms of granuloma formation, maintenance and necrosis].

Authors:  S Ehlers
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 9.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

10.  Frequent detection of multidrug-resistant pneumonia-causing bacteria in the pneumonia lung tissues of patients with hematological malignancies.

Authors:  Kunihiro Inai; Hiromichi Iwasaki; Sakon Noriki; Satoshi Ikegaya; Masanori Yamashita; Yoshiaki Imamura; Nobuo Takimoto; Hisataka Kato; Takanori Ueda; Hironobu Naikia
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.